A First-in-human, Dose-escalation Followed by Expansion Study to Assess the Safety and Preliminary Efficacy of a Bispecific Antibody OT-A201 As Monotherapy and in Combination Therapy in Patients with Selected Hematological Malignancies and Solid Tumors
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Bevacizumab (Primary) ; Lenalidomide (Primary) ; OTA 201 (Primary) ; Paclitaxel (Primary) ; Pomalidomide (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Onward Therapeutics
Most Recent Events
- 24 Jan 2024 According to a Biomunex Pharmaceuticals media release, the first patient has been enrolled in this study in 2023, thus triggered a milestone payment to Biomunex tied to the start of a Phase 1 clinical trial.
- 27 Jun 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2023 to 1 Jun 2023.
- 27 Jun 2023 Status changed from not yet recruiting to recruiting.